http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_dba3fb4f71ec123b8f06c93381563a3a
Outgoing Links
| Predicate | Object |
|---|---|
| family-name | Dolcetti |
| name | Riccardo Dolcetti |
| given-name | Riccardo |
| organization-name | Division of Experimental Oncology 1, Division of Pathology and Division of Medical Oncology, Oncologic Reference Center, Aviano, Italy **National Cancer Institute, 33081 Aviano, Italy 1Immunovirology and Biotherapy Unit and Division of Experimental Oncology 1 Center, Aviano Department of Tumor Biology, Karolinska Institute, Stockholm, Sweden. Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, IRCCSCRO Aviano National Cancer Institute, Aviano (PN), Italy. Istituto Di Ricovero e Cura a Carettere Scientifico, National Cancer Institute, Aviano, Italy Faculty of Medicine University of Queensland Herston Queensland Australia; Peter MacCallum Cancer Centre Melbourne Victoria Australia; Sir Peter MacCallum Department of Oncology University of Melbourne Melbourne Victoria Australia; Department of Microbiology and Immunology University of Melbourne Melbourne Victoria Australia Cancer Bio-Immunotherapy, Department of Translational Research, Centro di Riferimento Oncologico (CRO), National Cancer Institute, Aviano, Italy; University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Queensland, Australia University of Queensland Diamantina Institute, Translational Research Institute, University of Queensland Brisbane QLD Australia Microbiology-Immunology and Virology Unit; Immunovirology and Biotherapy Unit; Epidemiology Unit; Medical Oncology Department, Centro di Riferimento Oncologico, Istituto di Recovero e Cura a Carattere Scientifico, Aviano, Italy Cancer Bio-Immunotherapy Unit; CRO Aviano; IRCCS; National Cancer Institute; Aviano Pordenone Italy Cancer Bio-Immunotherapy Unit, Centro di Riferimento Oncologico - IRCCS; National Cancer Institute; Aviano PN Italy; University of Queensland Diamantina Institute, Translational Research Institute, University of Queensland; Brisbane QLD Australia (Experimental Oncology 1, Centro di Riferimento Oncologico, Aviano, Pordenone) Division of Experimental Oncology 1, Centro di Riferimento Oncologico, IRCCS, Istituto Nazionale Tumori, Aviano, Italy From the Divisions of Experimental Oncology 1, Medical Oncology, and Pathology, Centro di Riferimento Oncologico, Aviano; DIMO, Section of Internal Medicine and Clinical Oncology, University of Bari, Bari; and the Division of Microbiology, Pordenone City Hospital, Pordenone, Italy. Peter MacCallum Cancer Centre Melbourne Victoria Australia; Sir Peter MacCallum Department of Oncology The University of Melbourne Melbourne Victoria Australia; Department of Microbiology and Immunology The University of Melbourne Melbourne Victoria Australia; The University of Queensland Diamantina Institute Brisbane Queensland Australia Cancer Bio-Immunotherapy Unit, National Cancer Institute, Aviano, Italy Division of Experimental Oncology 1, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano (Pordenone 4Cancer Bioimmunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico, IRCCS National Cancer Institute, Aviano, Italy; From the Departments of Radiochemotherapy, Pathology, Ophthalmology, and Hematology, San Raffaele H Scientific Institute, Milan; Immunovirology and Biotherapy Unit, and Division of Experimental Oncology 1, Department of Pre-Clinical and Epidemiological Research, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico National Cancer Institute, Aviano, Italy; and First Department of Medicine, Semmelweis University, Budapest, Hungary Authors' Affiliations: 1Cancer Bio-Immunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico, IRCCS - National Cancer Institute, Aviano (PN), Italy; and 2Department of Pathology and CeRMS, University of Torino, Torino, Italy The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia2Cancer Bio-Immunotherapy Unit, Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy Immunovirology and Biotherapy Unit Cancer Bioimmunotherapy Unit, Department of Medical Oncology, CRO-IRCCS, National Cancer Institute, Aviano, Italy Cancer Bio-Immunotherapy Unit, Centro di Riferimento Oncologico, IRCCS-National Cancer Institute, Aviano (PN), Italy. University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia. Cancer Bio-Immunotherapy Unit, Centro di Riferimento Oncologico–Istituto di ricovero e cura a carattere scientifico, National Cancer Institute, Aviano, Italy;; University of Queensland Diamantina Institute, Translational Research Institute, University of Queensland, Brisbane, QLD, Australia; From the Division of Experimental Oncology 1, Centro di Riferimento Oncologico, Aviano, Italy. Andrés J.M. Ferreri, Silvia Govi, Silvia Mappa, Antonio Giordano Resti, Letterio Salvatore Politi, Claudio Doglioni, and Maurilio Ponzoni, San Raffaele Scientific Institute, Milan; Elisa Pasini and Riccardo Dolcetti, Centro di Riferimento Oncologico, Aviano; Francesco Zaja, Azienda Ospedaliera Universitaria Udine, Udine; Caterina Stelitano, Azienda Ospedaliera Malacrino'-Morelli, Reggio Calabria, Italy; Francesco Bertoni, Franco Cavalli, and Emanuele Zucca, Istituto Oncologico Svizzera Italiana,... Cancer Bio‐Immunotherapy Unit Department of Medical Oncology, CRO ‐ IRCCS National Cancer Institute Aviano Italy Immunovirology and Biotherapy Unit, CRO – IRCCS, National Cancer Institute, Aviano, Italy Sir Peter MacCallum Department of Oncology and Department of Microbiology and Immunology The University of Melbourne Melbourne Victoria Australia From the Divisions of Experimental Oncology 1 and Pathology, Centro di Riferimento Oncologico, Aviano; and Institute of Microbiology, University of Ferrara, Ferrara, Italy. Cancer Bioimmunotherapy Unit CRO-IRCCS, National Cancer Institute, Via F. Gallini 2, 33081 Aviano, Italy; Cancer Bioimmunotherapy Unit, Department of Medical Oncology, CRO National Cancer Institute, Via F. Gallini 2, 33081 Aviano, Italy 1Cancer Bio-Immunotherapy Unit, CRO-IRCCS, National Cancer Institute, Aviano, Italy. Authors' Affiliations: 1Cancer Bio-Immunotherapy Unit, 2Clinical and Experimental Pharmacology, 3Medical Oncology A, 4Experimental Oncology 1, 5Laboratory Medicine, and 6Pathology, C.R.O., IRCCS–National Cancer Institute, Aviano; 7Department of Oncology and Surgical Sciences, University of Padova/IOV, Padova; 8Areta International, Gerenzano; and 9Human Tumors Immunobiology Unit, Fondazione IRCCS - INT, Milan, Italy Cancer Bio-Immunotherapy Unit, Department of Translational Research, Centro di Riferimento Oncologico, IRCCS-National Cancer Institute, Aviano (PN), Italy; The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia Cancer Bioimmunotherapy Unit; Centro di Riferimento Oncologico; IRCCS; National Cancer Institute; Aviano Italy 2Immunovirology and Biotherapy Unit, Department of Pre-Clinical and Epidemiological Research, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, National Cancer Institute, Aviano, Italy; Departments of Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, IRCCS, Aviano (PN), Italy, Division of Experimental Oncology 1, Centro di Riferimento Oncologico, Aviano Cancer Bioimmunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico, IRCCS National Cancer Institute, Aviano, Italy Centro di Riferimento Oncologico Instituto di Ricovero e Cura a Carattere Scientifico, National Cancer Institute, 33081 Aviano, Pordenone, Italy; Division of Experimental Oncology3 and From the Divisione di Oncologia Sperimentale 2 and Divisione di Oncologia Sperimentale 1, CRO, Aviano, Italy; the Department of Pathology, City Hospital, Belluno, Italy; the Dipartimento di Biologia Evolutiva e Funzionale, Università degli Studi di Parma, Parma, Italy; and the Dipartimento di Scienze e Tecnologie Biomediche, Università degli Studi di Udine, Udine, Italy. 13The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia. Cancer Bio-Immunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico (CRO), Istituto di Ricovero e Cura a Caratiere Scientifico (IRCCS) National Cancer Institute, Aviano; Divisions of Experimental Oncology d Cancer Bioimmunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico, IRCCS National Cancer Institute, Aviano, Italy; Authors' Affiliations: 1Department of Surgery, Oncology and Gastroenterology, Section of Oncology and Immunology, University of Padova; 2Istituto Oncologico Veneto-IRCCS, Padova; and 3Cancer Bio-Immunotherapy Unit, CRO-IRCCS, National Cancer Institute, Aviano, Italy Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC 3000, Australia Cancer Bio-Immunotherapy Unit, Centro di Riferimento Oncologico, IRCCS, National Cancer Institute, Aviano, PN, Italy; University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia §CRO, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Pordenone, Italy; and |
Incoming Links
Total number of triples: 238.